A UMass Medical School clinical pharmacist will present on which specialty drugs are poised to be approved by the U.S. Food and Drug Administration (FDA), what those medications treat and how they will impact health plan budgets at the Academy of Managed Care Pharmacy’s AMCP Nexus 2017 conference, being held Oct. 16-19 in Dallas, Texas.
“Preparing your budget for the specialty drugs coming to market in 2019 is the key to succeeding in an uncertain market,” said Nicole Trask, PharmD. “I’ll talk about the potential place in therapy of these new agents and make projections about their budget impact.”
Specialty medications made up more than one-third of total drug spending in 2016, and drugs that treat diabetes and inflammatory conditions are among the most expensive.
Trask, a clinical consultant pharmacist in Clinical Pharmacy Services, will present “Bracing for Impact: Preparing for the 2019 Specialty Drug Spend,” from 3 to 4:30 p.m. Oct. 18. The evidence-based presentation discusses high-impact and high-cost drugs that are in the 2018-2019 pharmaceutical pipeline. Trask will discuss the efficacy, place in therapy and expected budget impacts of each medication.
Full session information can be found at the AMCP Nexus website.
Trask plays a vital role on UMass Medical School’s drug utilization review (DUR) team, which provides clients with internal controls to ensure members receive prescription drugs that are safe, medically necessary, and cost-effective. We develop detailed drug reviews and conduct both prospective and retrospective prescription pattern analyses for state Medicaid plans and managed care organizations across the U.S. to optimize treatment regimens, prevent adverse drug reactions, avoid therapeutic duplications, identify abuse/fraud issues, and more.